- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05390645
A Study of MFA-370 in Patients With Metastatic Urothelial Cancer (MANHATTAN)
An Open-label, Multi-center, Phase I/II Study of MFA-370 in Patients With Metastatic Urothelial Cancer
This is a multi-center study of MFA-370 in patients with metastatic urothelial cancer. The objective of the study is to assess the safety and efficacy of MFA-370, i.e.a combination of two approved pharmaceuticals today used within other indications. The combination was developed after the finding that a multidiseased man with e.g. muscle-invasive bladder cancer also was treated for his recent parasitic infection resulted in that the parasitic infection together with the cancer got a complete remission. After extensive experimental complementing studies a combination treatment called MFA-370 was developed supporting the rationale for this treatment.
This is the first clinical trial where the combination product MFA-370 is evaluated as anti-cancer treatment. Up to 50 patients will participate.
MFA-370 is taken orally once daily for up to 24 weeks. If the treatment is of clinical benefit for the patient, as assessed by the investigator, the treatment period can be prolonged to up to 2 years.
The patients will be monitored for safety, tolerability, pharmacokinetics, tumor response by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 and survival.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Austin Smith
- Phone Number: +44 7970 840160
- Email: austin.smith@ectinresearch.com
Study Locations
-
-
-
Stockholm, Sweden
- Karolinska University Hospital
-
Contact:
- Anders Ullén, MD
- Email: anders.ullen@ki.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed Informed Consent Form before any screening procedures
- ≥ 18 years of age on the day of giving informed consent
- Confirmed current metastatic urothelial carcinoma of the bladder, including the urethra and upper urinary tract. The patient needs to have progressive disease and/or symptomatic metastatic disease that is unresponsive to standard therapy. The patient must have received all available approved therapies before being eligible for the study unless contraindications or intolerance exist for one or several of them
- At least one lesion of measurable disease as defined by RECIST1.1 criteria based on CT or MRI scan within 2 weeks before start at Day -7
- World Health Organization (WHO) performance status 0-2
- Life expectancy ≥12 weeks
- Patients with reproductive potential will need to use accepted and highly effective means of contraception from study entry until at least 6 weeks for females (women of childbearing potential) and 3 months for males after study drug discontinuation
Main Exclusion Criteria:
- Known CNS metastatic lesions, or evidence of impaired blood-brain barrier as assessed by the investigator
- Have signs or symptoms of active COVID-19 infection or a positive COVID-19 Polymerase Chain Reaction (PCR) test during the screening period
- Impaired renal function by estimated Glomerular Filtration Rate (eGFR) <30 ml/min as per local assessment
- Laboratory values (hematology and biochemistry) within specified ranges to show appropriate organ function
- Clinically significant cardiac disease,
- Untreated or uncontrolled hypertension
- An underlying medical condition that precludes the ability to take oral medication daily
- Prohibited concomitant therapy
- The patient has had biologic, hormonal, anti-neoplastic chemotherapy, or radiation therapy other than palliative treatment within 4 weeks prior to screening except for medications with half-lives <5.5 days
- Hypersensitivity to the active ingredients or to any of the excipients listed in section 6.1 in respective Summary of Product Characteristics (SmPC)
- Any bleeding disorder or condition where there is an increased risk of bleeding
- A history of allergic reactions following intake of acetylsalicylic acid or NSAIDs
- A history of gastrointestinal bleeding or perforation
- Active or recurrent gastrointestinal ulcer
- Major surgery within 14 days before enrolment. (Note: trans-urethral resection of bladder tumor is not considered major surgery)
- For female patients of childbearing potential - pregnancy, as confirmed by a serum pregnancy test at screening, or breast-feeding
- Any other severe, acute, or chronic medical condition that would interfere with the conduct of the study or interpretation of the study results as judged by the investigator
- The patient has already participated in the study or been a screening failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MFA-370
MFA-370 once daily for up to 8 x 21 days.
|
MFA-370 is a treatment with a combination of two approved pharmaceuticals
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to 30 days safety follow up
|
Safety of MFA-370 measured by incidence and severity of AEs and serious SAEs with a causal relationship to MFA-370
|
Up to 30 days safety follow up
|
Incidence of dose interruptions, reductions, and treatment terminations due to AEs/SAEs
Time Frame: Up to 30 days safety follow up
|
Tolerability of MFA-370 measured by incidence of dose interruptions, reductions, and treatment terminations due to AEs/SAEs
|
Up to 30 days safety follow up
|
Overall Response Rate (ORR)
Time Frame: At 24 weeks
|
Anti-tumor activity of MFA-370 measured by Overall Response Rate (ORR), assessed by the investigator based on the assessment of the Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scans made by the responsible Radiologist at each site (scans assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1)
|
At 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR), Clinical Benefit Rate (CBR), Progression-Free Survival (PFS), Time to Progression (TTP), Best Overall Response (BOR)
Time Frame: Every six weeks up to 24 weeks
|
Anti-tumor activity of MFA-370 measured by ORR, CBR, PFS, TTP, BOR based on CT/MRI-scans assessed by Radiologist per RECIST 1.1
|
Every six weeks up to 24 weeks
|
Incidence and severity of AEs and SAEs
Time Frame: Up to 30 days after last dose
|
Safety of MFA-370 measured by incidence and severity of AEs and SAEs with a causal relationship to MFA-370
|
Up to 30 days after last dose
|
Incidence of dose interruptions, reductions, and treatment terminations due to AEs/SAEs
Time Frame: Up to 30 days after last dose
|
Tolerability of MFA-370 measured by incidence of dose interruptions, reductions, and treatment terminations due to AEs
|
Up to 30 days after last dose
|
Overall Survival
Time Frame: From the last dose until the date of death or up to 6 months after the last patient's end of treatment, whichever came first.
|
Effect of MFA-370 on Overall Survival
|
From the last dose until the date of death or up to 6 months after the last patient's end of treatment, whichever came first.
|
Plasma concentration profiles
Time Frame: From start of treatment until 29th day of treatment
|
To characterize the pharmacokinetic properties of MFA-370 with respect to time vs plasma concentration profiles
|
From start of treatment until 29th day of treatment
|
Peak Plasma Concentration (Cmax)
Time Frame: From start of treatment until 29th day of treatment
|
To characterize the pharmacokinetic properties of MFA-370 with respect to Cmax in plasma
|
From start of treatment until 29th day of treatment
|
Time to reach peak plasma concentration (tmax) of MFA-370 in plasma
Time Frame: From start of treatment until 29th day of treatment
|
To characterize the pharmacokinetic properties of MFA-370 with respect to tmax
|
From start of treatment until 29th day of treatment
|
Elimination half-life (t1/2) of MFA-370 in plasma
Time Frame: From start of treatment until 29th day of treatment
|
To characterize the pharmacokinetic properties of MFA-370 with respect to t1/2
|
From start of treatment until 29th day of treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ECT-001
- 2021-000068-30 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Urothelial Cancer
-
Gilead SciencesMerck KGaA, Darmstadt, GermanyRecruitingMetastatic Urothelial CancerItaly, United States, Korea, Republic of, Spain, Greece, France, Germany, United Kingdom, Turkey
-
Matthew GalskyBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingMetastatic Urothelial CancerUnited States
-
Astellas Pharma Global Development, Inc.Seagen Inc.CompletedMetastatic Urothelial CancerUnited States, Canada
-
Matthew GalskyIcahn School of Medicine at Mount Sinai; AstraZenecaCompletedMetastatic Urothelial CancerUnited States
-
University Hospital, GhentCompletedMetastatic Urothelial CancerBelgium
-
Monika Joshi, MDPfizer; Eisai Inc.; Big Ten Cancer Research ConsortiumTerminatedMetastatic Urothelial Cell CancerUnited States
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
National Cancer Institute (NCI)CompletedMetastatic Prostate Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage IV Renal... and other conditionsUnited States, Puerto Rico
-
AstraZenecaActive, not recruitingMetastatic Urothelial Cancer | Unresectable Locally Advanced Urothelial CancerUnited States, Italy, Spain, Canada, Hungary, Poland, Argentina, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, India, Japan, Philippines, Russian Federation, China, Taiwan, Israel, Australia, Bulgaria
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditionsUnited States
Clinical Trials on MFA-370
-
Bracco Diagnostics, IncTerminated
-
Bracco Diagnostics, IncCompleted
-
Seoul National University HospitalCompleted
-
Chong Kun Dang PharmaceuticalUnknownType 2 Diabetes MellitusKorea, Republic of
-
University of AarhusCompletedAllergy | Childhood AsthmaDenmark
-
Bracco Diagnostics, IncCompleted
-
Bracco Diagnostics, IncCompletedKidney DiseasesUnited States
-
Bracco Diagnostics, IncCompleted
-
Bracco Diagnostics, IncCompleted
-
Bracco Diagnostics, IncCompleted